Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Jazz Pharmaceuticals
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04541082CT.gov Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Medulloblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Onc 206 (this asset) | Jazz Pharmaceuticals | P1 | CC · 43 |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Irinotecan | Pfizer | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P2 | B |
| Cyclophosphamide | Theodore S. Johnson | P2 | B |
| Indoximod | Theodore S. Johnson | P2 | B |
| Etoposide | Theodore S. Johnson | P2 | B |
| Palbociclib | Pfizer | P2 | B |
| Tazemetostat | National Cancer Institute (NCI) | P2 | B |
+42 more in the Medulloblastoma cohort
Other indications for Onc 206
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Grade II Meningioma | — | P1 | CC · 43 |
| Ependymoma | — | P1 | CC · 43 |
| Central Nervous System Cancer | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Onc 206 in Medulloblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/onc-206-medulloblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →